Caris Life Sciences and Syapse Collaborate to Aggregate Oncology Data that Will Power Precision Medicine and Improve Patient Care
Posted by: Syapse 11/18/2015

Joint Effort Will Utilize Syapse Software to Combine Molecular, Genomic, Clinical Treatment and Outcomes Data to Support the Efforts of the Caris Centers of Excellence for Precision Medicine Network™

IRVING, Texas and PALO ALTO, Calif., November 18, 2015 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, and Syapse, the leading provider of precision medicine software, announced a collaboration to collect and combine molecular and genomic information with clinical treatment and outcomes data across the Caris Centers of Excellence for Precision Medicine Network™ (COE Network). The COE Network consists of leading cancer centers that have demonstrated a commitment to precision medicine and are working collaboratively to establish improved standards of care for molecular tumor profiling in oncology. Integration of Caris Molecular Intelligence®, Caris’ panomic, comprehensive tumor profiling service, with the Syapse Precision Medicine Platform, will provide a powerful real-time, point-of-care, clinical decision support system to enable more informed treatment decisions for each individual patient. Participating COE Network sites can use the integrated decision support system, and may use Syapse to further support their complete precision medicine workflows.

The collaboration enables patient outcomes data to be combined with the most comprehensive and clinically actionable molecular profile available. Caris Molecular Intelligence uses multiple technology platforms, including a proprietary 592-gene Next-Generation Sequencing (NGS) panel with full gene coverage to assess point mutations, indels, and copy number variations, alongside RNAseq, for select gene fusions, in addition to Immunohistochemistry (IHC), in situ Hybridization (ISH), and other platforms. This comprehensive interrogation of DNA, RNA, and protein expression enables Caris to include critical companion diagnostics for biomarkers such as ALK, ROS, HER2 and PDL1, and to provide associations for three key therapeutic classes: targeted therapies, immunotherapies and chemotherapeutics. 

The collaboration enables patient outcomes data to be combined with the most comprehensive and clinically actionable molecular profile available. Caris Molecular Intelligence uses multiple technology platforms, including a proprietary 592-gene Next-Generation Sequencing (NGS) panel with full gene coverage to assess point mutations, indels, and copy number variations, alongside RNAseq, for select gene fusions, in addition to Immunohistochemistry (IHC), in situ Hybridization (ISH), and others platforms. This comprehensive interrogation of the DNA, RNA, and protein expression enables Caris to include critical companion diagnostics for biomarkers such as ALK, ROS, HER2 and PDL1, and to provide associations for three key therapeutic classes: targeted therapies, immunotherapies and chemotherapeutics.

“We expect to profile 50,000 to 100,000 cancer patients annually across the COE Network. This is the largest oncology focused effort to combine comprehensive genomic and molecular profiling information with clinical outcomes data. It is sure to yield powerful information that will change the future of personalized medicine,” said David D. Halbert, Chairman and CEO of Caris Life Sciences. “We are excited to be working closely with Syapse and to further support the work of the Caris Centers of Excellence for Precision Medicine Network.”

Under the agreement, Syapse software will be used to enable the COE Network to develop a better understanding of cancer and the most effective means of treatment and to provide patients with better access to new therapies and clinical trials. Select COE Network members will use Syapse to capture key oncology-specific clinical data from electronic medical records, integrate clinical data with Caris Molecular Intelligence tumor profiling results, and aggregate de-identified data into Caris’ centralized instance of the Syapse Precision Medicine Platform for sharing across the COE Network. In addition, Syapse will enable COE Network members to participate in virtual tumor boards, where they can review cases, capture guidance, and disseminate knowledge throughout the Network.

“This collaboration gives participating COE Network members the decision support, clinical workflow and data aggregation tools they need to realize meaningful improvements in patient care,” said Jonathan Hirsch, President and Founder of Syapse. “Sharing the clinical and molecular profile of patients, alongside their treatments and outcomes, will enable members of the COE Network to collaboratively develop the best practices and clinical utility evidence needed to advance the practice of precision oncology.” 

About Caris Life Sciences®

Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company’s healthcare information and comprehensive tumor profiling service with more than 80,000 patients profiled, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature. Since 2009, Caris Life Sciences has tracked clinical and outcome data for certain patients undergoing tumor profiling, and has observed that patients treated with drugs consistent with their tumor profile show a significant increase in overall survival.  The company is also developing its ADAPT Biotargeting System™, a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com

About Syapse

Syapse software enables healthcare providers to deploy precision medicine programs. Leading academic and community healthcare providers use the Syapse Precision Medicine Platform to integrate complex genomic and clinical data to provide clinicians with actionable insights at point of care, enabling diagnosis, treatment, and outcomes tracking. Headquartered in Palo Alto, California, Syapse is backed by The Social+Capital Partnership and Safeguard Scientifics (NYSE:SFE). For more information, visit www.syapse.com.